Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization.

Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B.

Mod Pathol. 2007 Nov;20(11):1121-7.

2.

New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

Schalken JA, Hessels D, Verhaegh G.

Urology. 2003 Nov;62(5 Suppl 1):34-43. Review.

PMID:
14607216
3.

[The search for better markers for prostate cancer than prostate-specific antigen].

Schenk-Braat EA, Bangma CH.

Ned Tijdschr Geneeskd. 2006 Jun 10;150(23):1286-90. Review. Dutch.

PMID:
16821452
4.

[Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis].

Ruiz-Aragón J, Márquez-Peláez S.

Actas Urol Esp. 2010 Apr;34(4):346-55. Review. Spanish.

PMID:
20470697
5.

Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.

Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M.

Nat Clin Pract Urol. 2007 Jun;4(6):321-32. Review.

PMID:
17551536
6.

[Value of urinary PCA3 test for prostate cancer diagnosis].

Vlaeminck-Guillem V, Ruffion A, Andre J.

Prog Urol. 2008 May;18(5):259-65. doi: 10.1016/j.purol.2008.03.029. Review. French.

PMID:
18538269
7.
8.

PCA3 in the detection and management of early prostate cancer.

Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W.

Tumour Biol. 2013 Jun;34(3):1337-47. doi: 10.1007/s13277-013-0739-6. Review.

PMID:
23504524
9.

Progensa PCA3 test for prostate cancer detection.

de la Taille A.

Expert Rev Mol Diagn. 2007 Sep;7(5):491-7. Review.

PMID:
17892357
10.

PCA3 improves diagnosis of prostate cancer.

Kirby R.

Practitioner. 2007 Jan;251(1690):18, 21, 23. Review. No abstract available.

PMID:
17290852
Items per page

Supplemental Content

Support Center